Join the Network
Twitter Youtube
info@skincanada.org
Menu

Inflammatory Skin Diseases

  1. Hundal S, Cappelli J, Croitoru D, et al. Cost-Utility Analysis of Clinic-Based Deroofing versus Local Excision for Hidradenitis Suppurativa. J Am Acad Dermatol. Dec 8 2024;https://www.ncbi.nlm.nih.gov/pubmed/39657847
  2. Vallee S, Deneux V, Funaro D, et al. Long-term evolution of prepubertal-onset anogenital lichen sclerosus: A 35-year retrospective and cross-sectional study from a single tertiary care maternal and pediatric center. J Am Acad Dermatol. Dec 3 2024;https://www.ncbi.nlm.nih.gov/pubmed/39637982
  3. Eichenfield LF, Hebert AA, Harper JC, et al. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne in Children and Adolescents. J Drugs Dermatol. Dec 1 2024;23(12):1049-1057. https://www.ncbi.nlm.nih.gov/pubmed/39630680
  4. Armstrong AW, Bissonnette R, Chovatiya R, et al. Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis. Cutis. Oct 2024;114(4):122-127. https://www.ncbi.nlm.nih.gov/pubmed/39621574
  5. Choi UE, Deng J, Parthasarathy V, et al. Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis. J Am Acad Dermatol. Nov 28 2024;https://www.ncbi.nlm.nih.gov/pubmed/39615548
  6. Chiang N, Alhusayen R. Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments. J Cutan Med Surg. Nov 27 2024:12034754241300292. https://www.ncbi.nlm.nih.gov/pubmed/39604305
  7. Armstrong AW, Lebwohl M, Warren RB, et al. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials. JAMA Dermatol. Nov 27 2024;https://www.ncbi.nlm.nih.gov/pubmed/39602111
  8. Metko D, Mehta S, McMullen E, Piguet V. Biologic management of PASH syndrome: A systematic review. Arch Dermatol Res. Nov 19 2024;317(1):32. https://www.ncbi.nlm.nih.gov/pubmed/39560772
  9. van Straalen KR, Piguet V, Gudjonsson JE. Hidradenitis suppurativa: key insights into treatment success and failure. The Journal of clinical investigation. Nov 1 2024;134(21)https://www.ncbi.nlm.nih.gov/pubmed/39484718
  10. Merilleno ASP, Tadrous M, Ushcatz I, Zhao HJ, Drucker AM. Association between atopic dermatitis burden and sociodemographic index with dupilumab and tralokinumab utilization across 50 countries. Int J Dermatol. Oct 31 2024;https://www.ncbi.nlm.nih.gov/pubmed/39482808
  11. Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, comparative clinical study over 52 weeks. The British journal of dermatology. Oct 23 2024;https://www.ncbi.nlm.nih.gov/pubmed/39442018
  12. Manzar D, Suntres E, Abdi P, Alhusayen R. The Safety and Efficacy of Interleukin-17 Inhibitors for Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. J Cutan Med Surg. Oct 24 2024:12034754241290812. https://www.ncbi.nlm.nih.gov/pubmed/39445454
  13. Maazi M, Toy J, Gui XY, Piguet V. Off-Label Use of Tildrakizumab in Patients with Hidradenitis Suppurativa. J Cutan Med Surg. Oct 25 2024:12034754241291044. https://www.ncbi.nlm.nih.gov/pubmed/39450621
  14. Jack C, Drucker AM. Fears for tears? Targeted therapies for atopic dermatitis and ocular surface health. J Eur Acad Dermatol Venereol. Nov 2024;38(11):2053-2055. https://www.ncbi.nlm.nih.gov/pubmed/39450782
  15. Calvo M, Tejos-Bravo M, Passi-Solar A, et al. Pregabalin for Neuropathic Pain and Itch in Recessive Dystrophic Epidermolysis Bullosa: A Randomized Crossover Trial. JAMA Dermatol. Oct 23 2024;https://www.ncbi.nlm.nih.gov/pubmed/39441591
  16. Frazier W, Schneider L, Chu DK. Atopic Dermatitis: Updated Guidelines From the AAAAI/ACAAI Joint Task Force on Practice Parameters. Am Fam Physician. Oct 2024;110(4):437-439. https://www.ncbi.nlm.nih.gov/pubmed/39418559
  17. Li K, Piguet V, Croitoru D, et al. Hidradenitis Suppurativa and Maternal and Offspring Outcomes. JAMA Dermatol. Oct 16 2024;https://www.ncbi.nlm.nih.gov/pubmed/39412794
  18. Sy SMT, Eder L, Jerome D, et al. Prevalence and Predictors of Inflammatory Arthritis in Hidradenitis Suppurativa. Exp Dermatol. Oct 2024;33(10):e15194. https://www.ncbi.nlm.nih.gov/pubmed/39397373
  19. Nwaneri U, Heath C, Alexis A, Friedman A, Silverberg JI. Reducing disparities in the care of atopic dermatitis. Arch Dermatol Res. Oct 15 2024;316(10):688. https://www.ncbi.nlm.nih.gov/pubmed/39404903
  20. Shojaei D, Zabihi H, Al-Dehneem R, Shamma D, Croitoru DO. Emerging Topical Therapies for Pyoderma Gangrenosum: An Evidence-Based Review. J Cutan Med Surg. Oct 5 2024:12034754241285476. https://www.ncbi.nlm.nih.gov/pubmed/39367789
  21. Rayner DG, Liu M, Chu AWL, et al. Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials. The Journal of allergy and clinical immunology. Oct 2024;154(4):996-1007. https://www.ncbi.nlm.nih.gov/pubmed/38852861
  22. Khalaf R, Davalan W, AlHusayen R. Effectiveness of Weight Loss Drugs in the Management of Hiradenitis Suppurativa: A Systematic Review. J Cutan Med Surg. Oct 3 2024:12034754241285592. https://www.ncbi.nlm.nih.gov/pubmed/39361555
  23. Alexis AF, Gooderham M, Kwatra SG, et al. A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis. Dermatol Ther (Heidelb). Oct 2 2024;https://www.ncbi.nlm.nih.gov/pubmed/39358667
  24. Arora P, Brumley C, Arrington K, Hylwa S. Allergic Contact Dermatitis in Skin of Color: A Retrospective Study from a Comprehensive Patch Testing Center. Dermatitis. Sep 23 2024;https://www.ncbi.nlm.nih.gov/pubmed/39308405
  25. Kearns-Turcotte S, McCuaig C, Powell J, et al. Pediatric BASCULE syndrome in 42 patients: a peek into dysautonomia. J Am Acad Dermatol. Sep 21 2024;https://www.ncbi.nlm.nih.gov/pubmed/39313031
  26. Caucheteux SM, Piguet V. Hidradenitis Suppurativa Tunnels Invasive Transcriptional Signature. The Journal of investigative dermatology. Sep 24 2024;https://www.ncbi.nlm.nih.gov/pubmed/39320303
  27. Savinova I, Gooderham M, O’Toole A, Cy A, Bawazir M, Abu-Hilal M. Clinical Characteristics and Treatment Patterns of Pityriasis Rubra Pilaris: A Canadian Retrospective Study. J Cutan Med Surg. Sep 25 2024:12034754241287553. https://www.ncbi.nlm.nih.gov/pubmed/39323064
  28. Chu AWL, Rayner DG, Chu X, et al. Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. Oct 2024;133(4):437-444 e18. https://www.ncbi.nlm.nih.gov/pubmed/38901542
  29. Simpson EL, Eichenfield LF, Alonso-Llamazares J, et al. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials. JAMA Dermatol. Sep 18 2024;https://www.ncbi.nlm.nih.gov/pubmed/39292443
  30. Drucker AM, Thibau IJC, Mantell B, Dainty KN, Wyke M, Smith Begolka W. Consensus on a Patient-Centered Definition of Atopic Dermatitis Flare. JAMA Dermatol. Sep 11 2024;https://www.ncbi.nlm.nih.gov/pubmed/39259557
  31. De Benedetto A, Boguniewicz M, Ong PY, Chu DK, Schneider LC. Atopic Dermatitis (eczema) Guidelines 2023: Highlights. J Allergy Clin Immunol Pract. Sep 7 2024;https://www.ncbi.nlm.nih.gov/pubmed/39251015
  32. Haag C, Alexis A, Aoki V, et al. A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council. The British journal of dermatology. Sep 10 2024;https://www.ncbi.nlm.nih.gov/pubmed/39250758
  33. Lax SJ, Van Vogt E, Candy B, et al. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis. Clin Exp Allergy. Sep 2 2024;https://www.ncbi.nlm.nih.gov/pubmed/39219446
  34. Aw K, Chan HA, Sibbald C, Piguet V, Croitoru D. Familial Mediterranean fever and MEFV gene variants in hidradenitis suppurativa: A systematic review. J Eur Acad Dermatol Venereol. Aug 27 2024;https://www.ncbi.nlm.nih.gov/pubmed/39189846
  35. Drucker AM, Lam M, Prieto-Merino D, et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. JAMA Dermatol. Jul 17 2024;https://www.ncbi.nlm.nih.gov/pubmed/39018058
  36. Maronese CA, Piguet V, Marzano AV. IRAK4: A Novel Target in the Therapeutic Landscape of Hidradenitis Suppurativa? The Journal of investigative dermatology. Jul 16 2024;https://www.ncbi.nlm.nih.gov/pubmed/39023474
  37. Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. Jul 11 2024;https://www.ncbi.nlm.nih.gov/pubmed/38989857
  38. Wheeler KE, Chu DK, Schneider L. Updated Guidelines for Atopic Dermatitis-AAAAI/ACAAI Joint Task Force. JAMA Pediatr. Jul 8 2024;https://www.ncbi.nlm.nih.gov/pubmed/38976275
  39. Chu X, Wang J, Ologundudu L, et al. Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Allergy Clin Immunol Pract. Jul 2024;12(7):1879-1889 e8. https://www.ncbi.nlm.nih.gov/pubmed/38642709
  40. Ushcatz I, Zhao HJ, Tadrous M, et al. Association of Countries’ Atopic Dermatitis Burden and Sociodemographic Index with Topical Calcineurin Inhibitor Utilization. Dermatitis. Jul 3 2024;https://www.ncbi.nlm.nih.gov/pubmed/38959123
  41. Li K, Bouadi N, Jeremian R, Bi WG, Piguet V, Croitoru DO. A Comparative Analysis of Hidradenitis Suppurativa and Acne Inversa Webpages. Clin Exp Dermatol. Jul 3 2024;https://www.ncbi.nlm.nih.gov/pubmed/38959433
  42. Korman NJ, Warren RB, Bagel J, et al. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. J Dermatolog Treat. Dec 2024;35(1):2371045. https://www.ncbi.nlm.nih.gov/pubmed/38945549
  43. Gooderham MJ, de Bruin-Weller M, Weidinger S, et al. Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Dermatol Ther (Heidelb). Jul 2 2024;https://www.ncbi.nlm.nih.gov/pubmed/38954384
  44. Guenther L, Turchin I, Vender R, et al. Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis. Dermatol Ther (Heidelb). Jun 25 2024;https://www.ncbi.nlm.nih.gov/pubmed/38916719
  45. Seigel L, Shoaib S, Maughn K, et al. Health disparities in psoriasis: geographic barriers to access in the United States. J Dermatolog Treat. Dec 2024;35(1):2365820. https://www.ncbi.nlm.nih.gov/pubmed/38914420
  46. Sampath AJ, Westerkam LL, Blum FR, et al. Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens. The Journal of investigative dermatology. Jun 18 2024;https://www.ncbi.nlm.nih.gov/pubmed/38901775
  47. Chu AWL, Rayner DG, Chu X, et al. Topical corticosteroids for hives and itch (urticaria): systematic review and Bayesian meta-analysis of randomized trials. Ann Allergy Asthma Immunol. Jun 18 2024;https://www.ncbi.nlm.nih.gov/pubmed/38901542
  48. Armstrong AW, Alexis AF, Blauvelt A, et al. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). Jun 19 2024;https://www.ncbi.nlm.nih.gov/pubmed/38896380
  49. Vu D, Park M, Alhusayen R. Efficacy of Moxifloxacin as a Mono-antibiotic Therapy for Hidradenitis Suppurativa: A Retrospective Cohort Study. J Am Acad Dermatol. May 31 2024;https://www.ncbi.nlm.nih.gov/pubmed/38825077
  50. Jeremian R, Malinowski A, Oh ES, et al. Epigenetic and biological age acceleration in children with atopic dermatitis. J Allergy Clin Immunol Glob. Aug 2024;3(3):100275. https://www.ncbi.nlm.nih.gov/pubmed/38826624
  51. Baldwin H, Gold LS, Harper JC, et al. Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants. J Drugs Dermatol. Jun 1 2024;23(6):394-402. https://www.ncbi.nlm.nih.gov/pubmed/38834226
  52. Garcia-Romero MT, Brandling-Bennett HA, Pope E, et al. Responsiveness to Change of the Morphea Activity Measure in Pediatric Patients. JAMA Dermatol. Jun 5 2024;https://www.ncbi.nlm.nih.gov/pubmed/38837147
  53. Kircik LH, Stein Gold L, Gold M, et al. Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis. Dermatol Ther (Heidelb). May 9 2024;https://www.ncbi.nlm.nih.gov/pubmed/38724841
  54. Alexis A, Del Rosso JQ, Forman S, et al. Importance of treating acne sequelae in skin of color: 6-month phase IV study of trifarotene with an appropriate skincare routine including UV protection in acne-induced post-inflammatory hyperpigmentation. Int J Dermatol. Apr 29 2024;https://www.ncbi.nlm.nih.gov/pubmed/38685118
  55. Eichenfield LF, Simpson EL, Papp K, et al. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. Am J Clin Dermatol. May 2 2024;https://www.ncbi.nlm.nih.gov/pubmed/38698175
  56. Tyring S, Moore A, Morita A, et al. Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial. Clin Exp Dermatol. May 3 2024;https://www.ncbi.nlm.nih.gov/pubmed/38699939
  57. Simpson EL, de Bruin-Weller M, Hong HC, et al. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). May 3 2024;https://www.ncbi.nlm.nih.gov/pubmed/38700646
  58. Molnar BA, Levin L, Yun D, et al. Inpatient Management of Epidermolysis Bullosa: Consensus-Based Hands-On Instructions for Neonates and Post-Neonates. J Am Acad Dermatol. Apr 9 2024;https://www.ncbi.nlm.nih.gov/pubmed/38604489
  59. Park M, Vu D, Alhusayen R. Trimethoprim-Sulfamethoxazole as a Mono-Antibiotic Therapy for Hidradenitis Suppurativa. J Cutan Med Surg. Apr 9 2024:12034754241247520. https://www.ncbi.nlm.nih.gov/pubmed/38591774
  60. Panel AAJADG, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. Mar 2024;132(3):274-312. https://www.ncbi.nlm.nih.gov/pubmed/38108679
  61. Wan V, Habibi A, Abdi P, Mukovozov I, Asiniwasis RN, Maibach HI. Systematic scoping review on the barriers to access of biologics in moderate-to-severe adult atopic dermatitis. Australas J Dermatol. Mar 4 2024;https://www.ncbi.nlm.nih.gov/pubmed/38439194
  62. Zabihi H, Shojaei D, Seigel K, Al-Dehneem R, Piguet V, Croitoru DO. Evaluating the Clinical Utility of Sulfasalazine in the Treatment of Pyoderma Gangrenosum: A Systematic Review. J Cutan Med Surg. Mar 10 2024:12034754241238713. https://www.ncbi.nlm.nih.gov/pubmed/38462891
  63. Metko D, Mehta S, Piguet V. Cannabis Usage Among Patients With Hidradenitis Suppurativa: A Scoping Review. J Cutan Med Surg. Mar 10 2024:12034754241238719. https://www.ncbi.nlm.nih.gov/pubmed/38462895
  64. Riaz S, Emam S, Wang T, Gniadecki R. Negative impact of comorbidities on all-cause mortality of psoriasis patients is partially alleviated by biologic treatment: A real-world, case-control study. J Am Acad Dermatol. Feb 20 2024;https://www.ncbi.nlm.nih.gov/pubmed/38387852
  65. Ameen M, Alhusayen R, Brandi H, et al. Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis. Acta Derm Venereol. Feb 21 2024;104:adv24339. https://www.ncbi.nlm.nih.gov/pubmed/38380974
  66. Gladman DD, Chandran V, Rosen CF, et al. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA). J Rheumatol. Feb 15 2024;https://www.ncbi.nlm.nih.gov/pubmed/38359937
  67. Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. Dec 2023;152(6):1493-1519. https://www.ncbi.nlm.nih.gov/pubmed/37678572
  68. Chu AWL, Wong MM, Rayner DG, et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. Dec 2023;152(6):1470-1492. https://www.ncbi.nlm.nih.gov/pubmed/37678577
  69. Panel AAJADG, Chu DK, Schneider L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. Dec 18 2023;https://www.ncbi.nlm.nih.gov/pubmed/38108679
  70. Brandling-Bennett HA, Arkin LM, Chiu YE, et al. Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. Feb 9 2024;https://www.ncbi.nlm.nih.gov/pubmed/38342248
  71. Deodhar A, Blauvelt A, Lebwohl M, et al. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials. Arthritis research & therapy. Feb 12 2024;26(1):49. https://www.ncbi.nlm.nih.gov/pubmed/38347650
  72. Machlab K, Yeung J, Gooderham M. Risankizumab in Adults with Psoriatic Arthritis. Skin Therapy Lett. Nov 2023;28(6):1-6. https://www.ncbi.nlm.nih.gov/pubmed/38015960
  73. Asiniwasis R, Merati N, Roesler J, et al. ‘The Social and Home Environment: Impacts of Determinants of Health on Atopic Dermatitis, Pathways Towards Solutions, and Unique Considerations for Rural and Remote North American Indigenous Populations’. J Allergy Clin Immunol Pract. Nov 25 2023;https://www.ncbi.nlm.nih.gov/pubmed/38013155
  74. Schmid-Grendelmeier P, Gooderham MJ, Hartmann K, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. Allergy. Nov 21 2023;https://www.ncbi.nlm.nih.gov/pubmed/37988255
  75. Papp KA, Lebwohl MG, Thaci D, et al. Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study. BioDrugs. Nov 22 2023;https://www.ncbi.nlm.nih.gov/pubmed/37991693
  76. Zuberbier T, Abdul Latiff A, Aggelidis X, et al. A concept for integrated care pathways for atopic dermatitis-A GA(2) LEN ADCARE initiative. Clin Transl Allergy. Sep 2023;13(9):e12299. https://www.ncbi.nlm.nih.gov/pubmed/37746794
  77. Mastacouris N, Tannenbaum R, Strunk A, et al. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice: A HiSTORIC Consensus Statement. JAMA Dermatol. Sep 27 2023;https://www.ncbi.nlm.nih.gov/pubmed/37755725
  78. Merola JF, Parish LC, Guenther L, et al. Efficacy and Safety of Apremilast in Patients with Moderate-to-Severe Genital Psoriasis: Results from Discreet, a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial. J Am Acad Dermatol. Oct 16 2023;https://www.ncbi.nlm.nih.gov/pubmed/37852306
  79. Croitoru DO, Brooks SG, Nathanielsz N, et al. Predictors of severity in paradoxical psoriasis from biologic therapies: A systematic review. J Am Acad Dermatol. Feb 2023;88(2):471-473. https://www.ncbi.nlm.nih.gov/pubmed/35718193
  80. Croitoru DO, Piguet V. Methylglyoxal Autoimmunity: A Hidden Link in HS and Associated Diseases? The Journal of investigative dermatology. Feb 2023;143(2):183-185. https://www.ncbi.nlm.nih.gov/pubmed/36681420
  81. Seigel K, Croitoru D, Lena ER, Dienes S, Alsukait S, Piguet V. Utility of Rituximab in the Treatment of Hidradenitis Suppurativa: A Systematic Review. J Cutan Med Surg. Mar-Apr 2023;27(2):176-177. https://www.ncbi.nlm.nih.gov/pubmed/36789521
  82. Croitoru DO, Piguet V. T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris. The Journal of investigative dermatology. Aug 2023;143(8):1340-1341. https://www.ncbi.nlm.nih.gov/pubmed/36959025
  83. O’Toole A, Gooderham M. Topical Roflumilast for Plaque Psoriasis. Skin Therapy Lett. Sep 2023;28(5):1-4. https://www.ncbi.nlm.nih.gov/pubmed/37734074
  84. Metelitsa A, Delorme I, O’Sullivan D, Zeinab R, Legault M, Gooderham M. A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology. Skin Therapy Lett. Sep 2023;28(5):5-11. https://www.ncbi.nlm.nih.gov/pubmed/37734108
  85. Warren RB, French LE, Blauvelt A, et al. Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS). J Am Acad Dermatol. Nov 9 2023;https://www.ncbi.nlm.nih.gov/pubmed/37951245
  86. Joly-Chevrier M, Gelinas A, Ghazal S, et al. Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review. Cancers. Sep 7 2023;15(18)https://www.ncbi.nlm.nih.gov/pubmed/37760419
  87. Tan J, Draelos ZD, Gooderham MJ, et al. Influence of Season on Efficacy and Tolerability of Tazarotene 0.045% Lotion for the Treatment of Acne. J Clin Aesthet Dermatol. Sep 2023;16(9):42-45. https://www.ncbi.nlm.nih.gov/pubmed/37720201
  88. Alexis AF, Silverberg JI, Rice ZP, et al. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type. Ann Allergy Asthma Immunol. Nov 8 2023;https://www.ncbi.nlm.nih.gov/pubmed/37949351
  89. Gooderham MJ, Bissonnette R, Kalia S, et al. Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Cutan Med Surg. Aug 11 2023:12034754231191509. https://www.ncbi.nlm.nih.gov/pubmed/37571829
  90. Gniadecki R, Osman M, Hennesey D, O’Keefe S, Thomsen SF, Iyer A. Architecture of skin inflammation in psoriasis revealed by spatial transcriptomics. Clin Immunol. Nov 2023;256:109771. https://www.ncbi.nlm.nih.gov/pubmed/37708923
  91. Osman M, Martins KJB, Wong KO, et al. Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study. Scientific reports. Sep 30 2023;13(1):16444. https://www.ncbi.nlm.nih.gov/pubmed/37777591
  92. Ma Z, Johnson D, Gniadecki R, et al. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world single centre experience. Rheumatology (Oxford). Oct 5 2023;https://www.ncbi.nlm.nih.gov/pubmed/37796840
  93. Latzka J, Assaf C, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome – Update 2023. Eur J Cancer. Sep 18 2023;195:113343. https://www.ncbi.nlm.nih.gov/pubmed/37890355
  94. Graff P, Woerz D, Wilzopolski J, et al. Extracellular Matrix Remodeling in Atopic Dermatitis Harnesses the Onset of an Asthmatic Phenotype and Is a Potential Contributor to the Atopic March. The Journal of investigative dermatology. Oct 12 2023;https://www.ncbi.nlm.nih.gov/pubmed/37838332
  95. Nash P, Dutz JP, Peterson S, et al. Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes. BMJ Open. Nov 8 2023;13(11):e062306. https://www.ncbi.nlm.nih.gov/pubmed/37940157
  96. Drucker AM, Lam M, Elsawi R, et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. The British journal of dermatology. Oct 13 2023;https://www.ncbi.nlm.nih.gov/pubmed/37831594
  97. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. Nov 3 2023;https://www.ncbi.nlm.nih.gov/pubmed/37943240
  98. Davis DMR, Drucker AM, Alikhan A, et al. Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. Nov 3 2023;https://www.ncbi.nlm.nih.gov/pubmed/37943241
  99. Renert-Yuval Y, Del Duca E, Arents B, et al. Treat-To-Target in Dermatology: A Scoping Review and International Eczema Council Survey on the Approach in Atopic-Dermatitis. J Eur Acad Dermatol Venereol. Sep 12 2023;https://www.ncbi.nlm.nih.gov/pubmed/37700595
  100. Liu L, Yang Q, Su MW, Zhou Y. Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001). JAAD Case Rep. Sep 2023;39:150-151. https://www.ncbi.nlm.nih.gov/pubmed/37693929
  101. Colaco K, Lee KA, Akhtari S, et al. Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis. Arthritis Rheumatol. Sep 11 2023;https://www.ncbi.nlm.nih.gov/pubmed/37691498
  102. Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From a Multicountry Study. J Eur Acad Dermatol Venereol. Sep 5 2023;https://www.ncbi.nlm.nih.gov/pubmed/37669868
  103. Abdi P, Awad C, Anthony MR, et al. Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis. Arch Dermatol Res. Sep 4 2023;https://www.ncbi.nlm.nih.gov/pubmed/37665358
  104. Lee EY, Drucker AM. A detailed evaluation of dupilumab’s effect on sleep in adults with atopic dermatitis. The British journal of dermatology. Sep 2 2023;https://www.ncbi.nlm.nih.gov/pubmed/37658831
  105. Le AM, Gooderham M, Torres T. Abrocitinib for the treatment of atopic dermatitis. Immunotherapy. Sep 5 2023;https://www.ncbi.nlm.nih.gov/pubmed/37667972
  106. Yosipovitch G, Gooderham MJ, Stander S, et al. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2. Am J Clin Dermatol. Aug 25 2023;https://www.ncbi.nlm.nih.gov/pubmed/37624488
  107. Schachner LA, Alexis AF, Andriessen A, et al. Insights into acne and the skin barrier: Optimizing treatment regimens with ceramide-containing skincare. J Cosmet Dermatol. Aug 21 2023;https://www.ncbi.nlm.nih.gov/pubmed/37605504
  108. Zhu C, Gabrielli S, Khoury L, et al. Immunosenescence, Inflammaging and Dermatology: Insights and Opportunities. J Cutan Med Surg. Aug 18 2023:12034754231194009. https://www.ncbi.nlm.nih.gov/pubmed/37593990
  109. Beckett M, Tan J, Bonnardeaux E, et al. Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients. Rheumatology (Oxford). Aug 16 2023;https://www.ncbi.nlm.nih.gov/pubmed/37584672
  110. Kircik L, Alexis AF, Andriessen A, et al. Psoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis. J Drugs Dermatol. Aug 1 2023;22(8):773-778. https://www.ncbi.nlm.nih.gov/pubmed/37556521
  111. Alexis AF, Woolery-Lloyd H, Andriessen A, Heath C, Han G. INDIVIDUAL ARTICLE: An Algorithm for the Management of Atopic Dermatitis in People With Skin of Color. J Drugs Dermatol. Aug 1 2023;22(8):SF386361s3-SF386361s10. https://www.ncbi.nlm.nih.gov/pubmed/37556528
  112. Hamm C, Ramsoondar N, McGillis M, Waugh M, Gooderham M, Giroux LL. The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study. J Cutan Med Surg. Aug 9 2023:12034754231191458. https://www.ncbi.nlm.nih.gov/pubmed/37559454
  113. Eder L, Lee KA, Chandran V, et al. Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention. Arthritis Rheumatol. Aug 9 2023;https://www.ncbi.nlm.nih.gov/pubmed/37555242
  114. Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. Aug 6 2023;https://www.ncbi.nlm.nih.gov/pubmed/37553030
  115. Miller AE, Zhang D, Shields BE, et al. COVID-19 associated severe mucocutaneous blistering eruptions: A case series. Pediatr Dermatol. Aug 1 2023;https://www.ncbi.nlm.nih.gov/pubmed/37526023
  116. Guttman-Yassky E, Silverberg JI, Thaci D, et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. Aug 1 2023;https://www.ncbi.nlm.nih.gov/pubmed/37528500
  117. Almuhanna N, Tobe SW, Alhusayen R. Risk of chronic kidney disease in hospitalized patients with hidradenitis suppurativa. Dermatology. Jul 24 2023;https://www.ncbi.nlm.nih.gov/pubmed/37487485
  118. Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study. The British journal of dermatology. Jul 25 2023;https://www.ncbi.nlm.nih.gov/pubmed/37488811
  119. Gooderham MJ, Pink AE, Simpson EL, Silverberg JI, Guler E, Watkins M. Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice. Dermatol Ther (Heidelb). Jul 23 2023;https://www.ncbi.nlm.nih.gov/pubmed/37482564
  120. Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. Jul 17 2023;https://www.ncbi.nlm.nih.gov/pubmed/37455588
  121. Lam M, Spuls PI, Leshem YA, et al. Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis. The British journal of dermatology. Jul 12 2023;https://www.ncbi.nlm.nih.gov/pubmed/37434297
  122. Leducq S, Maruani A, Bodemer C, et al. Accurate diagnosis of acute hemorrhagic edema of infancy: a French multicenter observational study. Eur J Pediatr. Jul 11 2023;https://www.ncbi.nlm.nih.gov/pubmed/37432503
  123. Hardin J, Makadia R, Black S, et al. Characteristics and treatment pathways in pediatric and adult hidradenitis suppurativa: An examination using real world data. JAAD Int. Sep 2023;12:124-132. https://www.ncbi.nlm.nih.gov/pubmed/37409312
  124. Papp KA, Beecker J, Cooper C, et al. Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb). Jul 6 2023;https://www.ncbi.nlm.nih.gov/pubmed/37410208
  125. Mease P, Setty A, Papp K, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol. Jul 5 2023;https://www.ncbi.nlm.nih.gov/pubmed/37404160
  126. Scollan ME, Levin LE, Lucky AW, et al. Characterization of wound microbes in epidermolysis bullosa: A focus on Pseudomonas aeruginosa. Pediatr Dermatol. Jun 26 2023;https://www.ncbi.nlm.nih.gov/pubmed/37364926
  127. Starkey SY, Kashetsky N, Lam JM, Dutz J, Mukovozov IM. Chilblain-Like Lesions (CLL) Coinciding With the SARS-CoV-2 Pandemic in Children: A Systematic Review. J Cutan Med Surg. May-Jun 2023;27(3):277-284. https://www.ncbi.nlm.nih.gov/pubmed/37340564
  128. Kashetsky N, Turchin I. Utilization of Topical Ruxolitinib in Dermatology: A Review. Skin Therapy Lett. May 2023;28(3):8-13. https://www.ncbi.nlm.nih.gov/pubmed/37339609
  129. Bourkas AN, Lara-Corrales I. The role of nutrition, food allergies, and gut dysbiosis in immune-mediated inflammatory skin disease: a narrative review. Curr Opin Pediatr. Jun 13 2023;https://www.ncbi.nlm.nih.gov/pubmed/37335275
  130. Gupta AK, Talukder M, Carviel JL, Cooper EA, Piguet V. Combatting antifungal resistance: paradigm shift in the diagnosis and management of onychomycosis and dermatomycosis. J Eur Acad Dermatol Venereol. May 21 2023;https://www.ncbi.nlm.nih.gov/pubmed/37210652
  131. Stein Gold L, Thaci D, Thyssen JP, et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. Am J Clin Dermatol. May 17 2023;https://www.ncbi.nlm.nih.gov/pubmed/37195407
  132. Mehta H, Jack C, Maari C, et al. Oral prednisone regulates human skin T cells in delayed-type hypersensitivity reaction elicited by diphencyprone. Allergy. May 10 2023;https://www.ncbi.nlm.nih.gov/pubmed/37163280
  133. Strober B, Thaci D, Sofen H, et al. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. May 7 2023;https://www.ncbi.nlm.nih.gov/pubmed/37150956
  134. Cotton CH, Chen SX, Hussain SH, Lara-Corrales I, Zaenglein AL. Hidradenitis Suppurativa in Pediatric Patients. Pediatrics. Apr 27 2023;https://www.ncbi.nlm.nih.gov/pubmed/37102307
  135. Jann J, Gascon S, Drevelle O, et al. Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium. Biomater Adv. Apr 20 2023;150:213433. https://www.ncbi.nlm.nih.gov/pubmed/37104962
  136. Alsenaid A, Piguet V, Lansang P, Miller-Monthrope Y, Yeung J, Joseph M. Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab. J Cutan Med Surg. Apr 4 2023:12034754231167140. https://www.ncbi.nlm.nih.gov/pubmed/37014149
  137. Blauvelt A, Lebwohl M, Langley RG, et al. Malignancy Rates Through 5 Years of Follow-up in Patients With Moderate-to-Severe Psoriasis Treated With Guselkumab: Pooled Results From the VOYAGE 1 and VOYAGE 2 Trials. J Am Acad Dermatol. Apr 3 2023;https://www.ncbi.nlm.nih.gov/pubmed/37019386
  138. Finstad A, Glockler-Lauf SD, Almuhanna N, Saskin R, Alhusayen R. Investigating the risk of malignancy in elderly patients with psoriasis: A population-based retrospective matched cohort study. J Am Acad Dermatol. May 2023;88(5):1129-1131. https://www.ncbi.nlm.nih.gov/pubmed/37069801
  139. McMullen EP, Syed SA, Espiritu KD, et al. The Therapeutic Applications of Machine Learning in Atopic Dermatitis: A Scoping Review. J Cutan Med Surg. Apr 19 2023:12034754231168846. https://www.ncbi.nlm.nih.gov/pubmed/37073787
  140. Yeung J, Gooderham MJ, Hong HC, et al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective. J Am Acad Dermatol. Apr 19 2023;https://www.ncbi.nlm.nih.gov/pubmed/37074241
  141. Kristensen LE, Soliman AM, Papp K, et al. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology (Oxford). Feb 1 2023;62(2):629-637. https://pubmed.ncbi.nlm.nih.gov/35801915/
  142. Quaglino P, Scarisbrick J, Roccuzzo G, et al. Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey. J Eur Acad Dermatol Venereol. Apr 2023;37(4):680-688. https://pubmed.ncbi.nlm.nih.gov/36606565/
  143. Gupta AK, Wang T, Polla Ravi S, Bamimore MA, Piguet V, Tosti A. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. J Eur Acad Dermatol Venereol. Apr 2023;37(4):666-679. https://pubmed.ncbi.nlm.nih.gov/36478475/
  144. Eichenfield LF, Stein Gold L, Kircik LH, et al. Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study. Pediatr Dermatol. Mar 22 2023;https://pubmed.ncbi.nlm.nih.gov/36949579/
  145. Blauvelt A, Thaçi D, Papp KA, et al. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. The British journal of dermatology. Mar 22 2023;https://pubmed.ncbi.nlm.nih.gov/36944555/
  146. Croitoru DO, Piguet V. T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris. The Journal of investigative dermatology. Mar 21 2023;https://pubmed.ncbi.nlm.nih.gov/36959025/
  147. Abduelmula A, Gooderham MJ. Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion. J Cutan Med Surg. Mar 21 2023:12034754231163541. https://pubmed.ncbi.nlm.nih.gov/36942447/
  148. Papp KA, Melosky B, Sehdev S, et al. Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatol Ther (Heidelb). Mar 16 2023;https://pubmed.ncbi.nlm.nih.gov/36929121/
  149. Taylor S, Elbuluk N, Grimes P, et al. Treatment recommendations for acne-associated hyperpigmentation: results of a Delphi consensus process and literature review. J Am Acad Dermatol. Mar 14 2023;https://pubmed.ncbi.nlm.nih.gov/36924935/
  150. Bowie AC, Tadrous M, Thiruchelvam D, et al. A comparison of family physician and dermatologist topical corticosteroid prescriptions: A population-based cross-sectional study. J Am Acad Dermatol. Mar 11 2023;https://pubmed.ncbi.nlm.nih.gov/36914480/
  151. Kimball AB, Prens EP, Passeron T, et al. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a Phase 2, randomized, placebo-controlled trial. Dermatol Ther (Heidelb). Mar 9 2023:1-13. https://pubmed.ncbi.nlm.nih.gov/36892753/
  152. Draelos ZD, Adam DN, Hong CH, et al. Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial. The British journal of dermatology. Mar 9 2023;https://pubmed.ncbi.nlm.nih.gov/36890712/
  153. Bourkas AN, Pope E. Oral ivermectin treatment for an infant with crusted scabies. Cmaj. Mar 6 2023;195(9):E334. https://pubmed.ncbi.nlm.nih.gov/36878546/
  154. García-Romero MT, Tollefson M, Pope E, et al. Development and validation of the morphea activity measure in patients with pediatric morphea. JAMA Dermatol. Mar 1 2023;159(3):299-307. https://pubmed.ncbi.nlm.nih.gov/36753150/
  155. Maleki-Yazdi KA, Heen AF, Zhao IX, et al. Values and preferences of patients and caregivers regarding treatment of atopic dermatis (eczema): a systematic review. JAMA Dermatol. Mar 1 2023;159(3):320-330. https://pubmed.ncbi.nlm.nih.gov/36696136/
  156. Alavi A, Anand N, Yamanaka-Takaichi M, et al. Evaluating the hidradenitis odor and drainage scale (HODS): A new validated potential instrument to assess odor and drainage in hidradenitis suppurativa-A cross-sectional study. JAAD Int. Mar 2023;10:75-76. https://pubmed.ncbi.nlm.nih.gov/36688101/
  157. Liy-Wong C, Tarango C, Pope E, et al. Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. Orphanet J Rare Dis. Feb 23 2023;18(1):38. https://pubmed.ncbi.nlm.nih.gov/36823529/
  158. Kokolakis G, Warren RB, Strober B, et al. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology. Feb 22 2023;188(3):330-340. https://pubmed.ncbi.nlm.nih.gov/36751950/
  159. Lebwohl MG, Hebert AA, Gooderham MJ. Roflumilast cream vs vehicle cream and chronic plaque psoriasis-reply. Jama. Feb 21 2023;329(7):595. https://pubmed.ncbi.nlm.nih.gov/36809324/
  160. Seigel K, Croitoru D, Lena ER, Dienes S, Alsukait S, Piguet V. Utility of rituximab in the treatment of hidradenitis suppurativa: a systematic review. J Cutan Med Surg. Feb 14 2023:12034754231154261. https://pubmed.ncbi.nlm.nih.gov/36789521/
  161. Wollenberg A, Kircik L, Simpson E, et al. Pooled analysis of baricitinib tolerability in patients with atopic dermatitis in relation to acne, headache, and gastrointestinal events from 8 clinical trials. Dermatitis. Feb 6 2023;https://pubmed.ncbi.nlm.nih.gov/36749121/
  162. Aaron M, Ramien ML, Powell J, et al. A retrospective single-centre case series of paediatric blistering severe cutaneous adverse reactions (SCARs): evaluation using new diagnostic classification confirms value of British Association of Dermatologists’ guidelines. Clin Exp Dermatol. Feb 3 2023;https://pubmed.ncbi.nlm.nih.gov/36733210/
  163. Gooderham M, Kircik L, Zirwas M, et al. The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, Phase 2 proof of concept study. J Drugs Dermatol. Feb 1 2023;22(2):139-147. https://pubmed.ncbi.nlm.nih.gov/36745371/
  164. Liu J, Cices A, Kaufman B, Sanabria-Gonzalez I, Alexis A. Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color. J Drugs Dermatol. Feb 1 2023;22(2):165-173. https://pubmed.ncbi.nlm.nih.gov/36745370/
  165. Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. Feb 1 2023;159(2):182-191. https://pubmed.ncbi.nlm.nih.gov/36630140/
  166. Gooderham M, Papp KA, Lynde C, et al. Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry. Dermatol Ther (Heidelb). Feb 2023;13(2):535-553. https://pubmed.ncbi.nlm.nih.gov/36562944/
  167. Musters AH, Broderick C, Prieto-Merino D, et al. The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry. J Eur Acad Dermatol Venereol. Feb 2023;37(2):365-381. https://pubmed.ncbi.nlm.nih.gov/36169355/
  168. Du AX, Ali Z, Ajgeiy KK, et al. Machine learning model for predicting outcomes of biologic therapy in psoriasis. J Am Acad Dermatol. Jan 30 2023;https://pubmed.ncbi.nlm.nih.gov/36720368/
  169. Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. Jan 27 2023;https://pubmed.ncbi.nlm.nih.gov/36708097/
  170. Ong PY, Boguniewicz J, Chu DK. Skin Antiseptics for Atopic Dermatitis: Dissecting Facts From Fiction. J Allergy Clin Immunol Pract. Jan 23 2023;https://pubmed.ncbi.nlm.nih.gov/36702247/
  171. Zinter MS, Markovic D, Asaro LA, et al. Tight Glycemic Control, Inflammation, and the ICU: Evidence for Heterogeneous Treatment Effects in Two Randomized Controlled Trials. Am J Respir Crit Care Med. Jan 19 2023;https://pubmed.ncbi.nlm.nih.gov/36656551/
  172. Bourkas AN, Pope E, Mendoza-Londono R, Kamath BM, Lara-Corrales I. Early diagnosis of ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis syndrome: A case report. Pediatr Dermatol. Jan 19 2023;https://pubmed.ncbi.nlm.nih.gov/36655593/
  173. Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. Jan 11 2023;https://pubmed.ncbi.nlm.nih.gov/36641009/
  174. Blauvelt A, Pariser DM, Tyring S, et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. J Dermatol Sci. Jan 9 2023;https://pubmed.ncbi.nlm.nih.gov/36690571/
  175. Sidbury R, Alikhan A, Bercovitch L, et al. Executive Summary: American Academy of Dermatology Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. Jan 6 2023;https://pubmed.ncbi.nlm.nih.gov/36623556/
  176. Williams JC, Alhusayen R, Guilbault S, et al. Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 Registry. Dermatology. 2023;239(2):283-286. https://pubmed.ncbi.nlm.nih.gov/36566748/
  177. Loo WJ, Turchin I, Prajapati VH, et al. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. J Cutan Med Surg. Jan-Feb 2023;27(1_suppl):3s-24s. https://pubmed.ncbi.nlm.nih.gov/36519621/
  178. Papp KA, Gooderham M, Dei-Cas I, et al. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatol Ther (Heidelb). Jan 2023;13(1):269-283. https://pubmed.ncbi.nlm.nih.gov/36496547/
  179. Voisin A, Al-Ali A, Abduelmula A, Gooderham MJ. Reasons for the Termination of Interleukin-17 Inhibitor Medications in the Treatment of Plaque Psoriasis: A Real-World Retrospective Study. J Cutan Med Surg. Jan-Feb 2023;27(1):67-69. https://pubmed.ncbi.nlm.nih.gov/36471620/
  180. Gulliver W, Gooderham MJ, Zhu B, et al. Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program. Dermatol Ther (Heidelb). Jan 2023;13(1):235-244. https://pubmed.ncbi.nlm.nih.gov/36436161/
  181. Capozza K, Funk M, Hering M, et al. Patients’ and Caregivers’ Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries. J Allergy Clin Immunol Pract. Jan 2023;11(1):264-273.e1. https://pubmed.ncbi.nlm.nih.gov/36332836/
  182. Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies. The Journal of allergy and clinical immunology. Jan 2023;151(1):172-181. https://pubmed.ncbi.nlm.nih.gov/36195170/
  183. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, et al. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The Journal of allergy and clinical immunology. Jan 2023;151(1):147-158. https://pubmed.ncbi.nlm.nih.gov/36191689/
  184. Abduelmula A, Mufti A, Mistry J, et al. Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review. J Cutan Med Surg. Jan-Feb 2023;27(1):73-75. https://pubmed.ncbi.nlm.nih.gov/36189927/
  185. Pavel AB, Del Duca E, Cheng J, et al. Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases. Allergy. Jan 2023;78(1):178-191. https://pubmed.ncbi.nlm.nih.gov/36178084/
  186. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. Jan 2023;88(1):40-51. https://pubmed.ncbi.nlm.nih.gov/36115523/
  187. Blauvelt A, Kircik L, Papp KA, et al. Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. Jan 2023;37(1):137-146. https://pubmed.ncbi.nlm.nih.gov/36066323/
  188. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. Jan 2023;88(1):29-39. https://pubmed.ncbi.nlm.nih.gov/35820547/
  189. Haberman RH, MacFarlane KA, Catron S, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. Dec 23 2022;12(12):e063650. https://pubmed.ncbi.nlm.nih.gov/36564123/
  190. Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. Dec 17 2022;https://pubmed.ncbi.nlm.nih.gov/36538948/
  191. Jelousi S, Sharma D, Alexis A, Murase JE. The Impact of Global Health Disparities on Atopic Dermatitis in Displaced Populations: Narrowing the Health Equity Gap for Patients with Skin of Color. Dermatol Ther (Heidelb). Dec 2022;12(12):2679-2689. https://pubmed.ncbi.nlm.nih.gov/36261772/
  192. Ding J, Joseph M, Chawla S, et al. Disparities in psoriasis clinical trials: A cross-sectional analysis. J Am Acad Dermatol. Dec 2022;87(6):1386-1389. https://pubmed.ncbi.nlm.nih.gov/36113618/
  193. Reich K, Lio PA, Bissonnette R, et al. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. Dec 2022;10(12):3228-3237.e2. https://pubmed.ncbi.nlm.nih.gov/36108923/
  194. Eveillard LA, Quartier P, Ouldali N, et al. Association of atypical skin manifestations at the onset of systemic juvenile idiopathic arthritis with difficult-to-treat disease: A retrospective multicenter study. J Am Acad Dermatol. Dec 2022;87(6):1425-1428. https://pubmed.ncbi.nlm.nih.gov/35963289/
  195. Muntyanu A, Le M, Ridha Z, et al. Novel role of long non-coding RNAs in autoimmune cutaneous disease. J Cell Commun Signal. Dec 2022;16(4):487-504. https://pubmed.ncbi.nlm.nih.gov/34346026/
  196. Alexis A, Woolery-Lloyd H, Andriessen A, Kang S, Rodriguez D, Callender V. Racial/Ethnic Variations in Acne: A Practical Algorithm for Treatment and Maintenance, Including Skincare Recommendations for Skin of Color Patients With Acne. J Drugs Dermatol. Nov 1 2022;21(11):s13223-s132214. https://pubmed.ncbi.nlm.nih.gov/36342741/
  197. Mahmood F, Nguyen A, Muntyanu A, et al. Prevalence and Incidence of Localized Scleroderma: A Qualitative Systematic Review. J Cutan Med Surg. Nov-Dec 2022;26(6):632-633. https://pubmed.ncbi.nlm.nih.gov/36225142/
  198. Mahé E, Beauchet A, Hadj-Rabia S, et al. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists. Dermatol Ther. Nov 2022;35(11):e15828. https://pubmed.ncbi.nlm.nih.gov/36107157/